Human IL-17/IL-17A (Research Grade Secukinumab Biosimilar) Antibody

Catalog #: MAB9492 Datasheet / COA / SDS

Recombinant Monoclonal Antibody For Research Use Only

Catalog #	Availability	Size / Price	Qty
MAB9492-100
MAB9492-SP

2 Images

All IL-17/IL-17A Antibodies

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human IL-17/IL-17A (Research Grade Secukinumab Biosimilar) Antibody Summary

Species Reactivity

Human

Source

Recombinant Monoclonal Human IgG₁ Clone # Hu71

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Human IL‑17/IL‑17A

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Label

Unconjugated

Scientific Data

ELISA

View Larger

Human IL‑17/IL‑17A ELISA Standard Curve Direct ELISA binding curve demonstrating the recognition of Human Anti-Human IL‑17/IL‑17A (Research Grade Secukinumab Biosimilar) Monoclonal Antibody (Catalog # MAB9492) to IL‑17/IL‑17A. The target protein was coated onto the microplate well surface, followed by binding of the antibody. A goat anti-human HRP conjugate was used for detection.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-17/IL-17A

Secukinumab is a humanized monoclonal IgG1/k antibody against proinflammatory cytokine IL-17A, and is approved for the treatment of plaque psoriasis, as well as enthesitis-related arthritis, and ankylosing spondylitis. Secukinumab binds to IL-17A with high specificity preventing the interaction with the IL-17 receptor and subsequent activation of the pathway leading to inflammation seen in these disease states. Data has shown that in the presence of secukinumab results in enhanced levels of free unbound IL-17A in the serum indicating inhibition of binding to IL-17A receptor resulting in reduced inflammation.

Long Name

Interleukin 17

Entrez Gene IDs

3605 (Human); 16171 (Mouse); 301289 (Rat); 449530 (Porcine); 481837 (Canine); 102119976 (Cynomolgus Monkey)

Alternate Names

CTLA8; CTLA-8; CTLA8cytotoxic T-lymphocyte-associated serine esterase 8; Cytotoxic T-lymphocyte-associated antigen 8; IL17; IL-17; IL17A; IL-17A; IL-17Acytotoxic T-lymphocyte-associated protein 8; IL-17CTLA-8; IL17interleukin-17A; interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8); interleukin 17A